Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
IL2-H52H8 | Human | Human IL-2 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
IL2-H82E4 | Human | Biotinylated Human IL-2 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
IL2-H82F3 | Human | Biotinylated Human IL-2 Protein, Fc,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
IL2-H4113 | Human | Human IL-2 Protein, Tag Free | ![]() |
![]() ![]() |
![]() ![]() ![]() ![]() |
Human IL-2 R beta, Fc Tag (Cat. No. ILB-H5253) captured on CM5 chip via anti-human IgG Fc antibody, can bind IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 0.6 μM as determined in a SPR assay (Biacore T200) (Routinely tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Recombinant Human Interleukin-2 Injection (Beijing Four Rings Biopharmaceutical) | Approved | Beijing Four Rings Biopharmaceutical | Recombinant Human Interleukin-2 Injection | cfda | Renal carcinoma, Melanoma | 2016-04-29 | Renal carcinoma, Melanoma | Details | ||
Thalidomide | NSC-527179; NSC-66847; K-17,NSC527179; NSC66847; K17,NSC 527179; NSC 66847; K 17 | Approved | Celgene | THALOMID | fda | Erythema nodosum leprosum (ENL), Multiple myeloma (MM) | CELGENE | 1998-07-16 | Erythema nodosum leprosum (ENL), Multiple myeloma (MM) | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
VPM-4001 | VPM-4001; VPM-4-001,VPM 4001; VPM 4 001,VPM4001 | Phase Ⅱ | Memorial Sloan-Kettering Cancer Center, Vakzine Projekt Management | Prostate cancer | Details |
Interleukin-2 (Amgen) | Phase Ⅱ | Amgen | Cancer | Details | |
AdCAIL-2 (McMaster University) | Phase Ⅰ | McMaster University | Breast cancer, Melanoma | Details | |
Vector-based gene therapy (National Institutes of Health) | Phase Ⅰ | National Institutes of Health | Colon cancer, Renal cell carcinoma, Melanoma | Details | |
Interleukin-2 gene therapy (St Jude Children's Research Hospital) | Phase Ⅰ | St Jude Children's Research Hospital, National Cancer Institute | Neuroblastoma | Details | |
Interleukin-2 gene therapy (UCLA) | Phase Ⅰ | University of California at Los Angeles | Colon cancer, Prostate cancer, Melanoma | Details | |
Albumin-interleukin-2 | Phase Ⅰ | CSL Behring, Human Genome Sciences | Cancer | Details | |
Pegylated interleukin-2 (Chiron) | Phase Ⅱ | Chiron | HIV infection, Squamous cell carcinoma of head and neck cancer (SCCHN), Metastatic cancer | Details | |
T20K | T-20K | Phase Ⅰ | Cyxone | Multiple sclerosis (MS) | Details |
Tucotuzumab celmoleukin | EMD-273066; huKS-IL2; KS-IL2 | Phase Ⅱ | EMD Lexigen, Merck Serono | Small cell lung cancer (SCLC), Ovarian cancer | Details |
Gene therapy for renal cell carcinoma (Shire) | Phase Ⅰ | Shire | Renal carcinoma | Details | |
Human interleukin-2 biosimilar (Amoytop Biotech/BioGeneric Pharma) | rHuIL-2 | Phase Not Specified | BioGeneric, Xiamen Amoytop Biotech | Metastatic renal cell carcinoma, Melanoma | Details |
Darleukin/fibromun | L19-IL-2/ L19-TNF-α | Phase Ⅲ | Philogen | Melanoma | Details |
Interleukin-2 (Roussel Uclaf) | U-49637; RU-49637; IL-2 (Roussel Uclaf) | Phase Ⅲ | Sanofi, Transgene | Cancer | Details |
TG-1031 | TG-1031; pTG-1031 | Phase Ⅱ | Transgene | Prostate cancer, Breast cancer | Details |
S-95007 | S-95007 | Phase Ⅱ | Servier | Immune-inflammatory diseases, Immunological disorders | Details |
Interleukin-2 controlled release (Avadel Pharmaceuticals) | Phase Ⅱ | Avadel Pharmaceuticals | Renal carcinoma | Details | |
ITI-1000 | ITI-1000 | Phase Ⅱ | Immunomic Therapeutics, Duke University Medical Center | Glioblastoma | Details |
HBAI-20 | HBAI-20; HBAI-20-CyTuVax | Phase Ⅱ | CyTuVax | HBV infection | Details |
IL-2 gene therapy (Imperial Cancer Research Technology) | Phase Ⅰ | Cancer Research UK | Melanoma | Details | |
Bifikafusp alfa | L19-IL-2 | Phase Ⅲ | Philogen, Bayer | Diffuse large B cell lymphoma, Atherosclerosis, Renal carcinoma, Head and neck cancer, Pancreatic cancer, Melanoma | Details |
TG-4010 | TG-4010; VV-MUC-IL2 | Phase Ⅲ | Transgene | Non small cell lung cancer (NSCLC) | Details |
Whole cell vaccine (Oncbiomune) | Phase Not Specified | Oncbiomune | Breast cancer | Details | |
PMI-001 | PMI-001,PMI 001,PMI001 | Phase Ⅲ | Phytomedics | Lupus vulgaris, Psoriasis, Multiple sclerosis (MS), Rheumatoid arthritis (RA) | Details |
Interleukin-2 gene therapy (Institute of Cancer Research UK) | Phase Ⅰ | Institute of Cancer Research | Melanoma | Details | |
Autologous tumor cell vaccine (NCI) | Phase Ⅱ | H. Lee Moffitt Cancer Center and Research Institute, National Cancer Institute, Chiron | Renal carcinoma | Details | |
AC-9401 | AC-9401 | Phase Ⅱ | AntiCancer Inc | Cancer | Details |
ALVAC-hIL-2 | ALVAC-IL-2; ALVAC-hIL-2; vCP277,ALVAC-IL 2; ALVAC-hIL 2,ALVAC-IL2; ALVAC-hIL2 | Phase Ⅱ | Sanofi Pasteur | Cancer | Details |
Interleukin-2 gene therapy (Valentis) | VLTS-587 | Phase Ⅱ | Valentis | Lung cancer, Head and neck cancer, Melanoma | Details |
DAB-486-IL-2 | Phase Ⅱ | Seragen, Lilly | Type 1 diabetes, HIV infection, Lymphoma, Rheumatoid arthritis (RA), Kaposi's sarcoma | Details |
This web search service is supported by Google Inc.